Ruxolitinib Cream Approved for Children Aged 2-11 With AD

Ruxolitinib is the first topical JAK inhibitor approved in the US for pediatric AD.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/ruxolitinib-cream-approved-children-aged-2-11-atopic-2025a1000ow3?src=rss

Author :

Publish date : 2025-09-19 05:22:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Ruxolitinib Cream Approved for Children Aged 2-11 With AD

Doctor sexual misconduct hearings too lenient, says UK review

Gene Therapy Shows Signal for Improving Retinal Function

Related Posts

Rising CVD Risks: Pregnancy an Opportunity to Screen

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

Rising CVD Risks: Pregnancy an Opportunity to Screen

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

What Vaccine Was Tied to Longer Cancer Survival?

PFAS Exposure and Brain Development; Food Insecurity and Blood Pressure

Categories

Archives